Journal
LEUKEMIA & LYMPHOMA
Volume 56, Issue 3, Pages 587-593Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2015.1011641
Keywords
Fludarabine; alemtuzumab; 17p; TP53; fluorescence in situ hybridization
Categories
Ask authors/readers for more resources
Patients with chronic lymphocytic leukemia (CLL) carrying deletion of 17p (17p-) or mutations of TP53 have a uniquely poor prognosis related to increased propensities to progress to symptomatic disease, poor responses to chemo(immuno) therapy and high rates of Richter transformation. Both traditional fludarabine, cyclophosphamide and rituximab (FCR)-based chemoimmunotherapy and alemtuzumab-based regimens are inadequate in controlling 17p- CLL durably, and allogeneic stem cell transplant holds the only prospect for long-term survival. Recent advances in targeted therapies have resulted in novel agents such as B-cell receptor pathway and BCL2 antagonists yielding high response rates in 17p- CLL, but these patients continue to relapse at an increased rate when compared to patients without 17p-. In this review, we discuss the current evidence base for making therapeutic decisions in this difficult disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available